You are here: Home: Audio Program Guide: CCU 2 | 2006 Audio
 
  Go to interview with Joel Tepper, MD
Go to interview with J Randolph Hecht, MD
Go to interview with Josep Tabernero, MD
  To listen to individual tracks, click the on the headphone.
To download tracks, right-click on the one you wish to download.
Joel Tepper, MD
Professor and Chair
Department of Radiation Oncology
University of North Carolina School of Medicine
Chapel Hill, North Carolina
  
  Click here to download the entire interview  
Track 1 Introduction by Neil Love, MD
Track 2 Increased incidence of rectal cancer in men treated with radiation therapy for prostate cancer
Track 3 Impact of T stage and N stage on survival of patients with rectal cancer
Track 4 Impact of the number of retrieved nodes on outcome in patients with rectal cancer
Track 5 Adjuvant chemotherapy following neoadjuvant chemoradiation therapy for rectal cancer
Track 6 Preoperative evaluation of patients with rectal cancer
Track 7 Indications for sphincter-sparing surgical procedures in rectal cancer
Track 8 Impact of surgeon experience on outcome in rectal cancer
Track 9 NSABP neoadjuvant and ECOG adjuvant trials
Track 10 Infusional 5-FU versus capecitabine in combination with radiation therapy for rectal cancer
Track 11 Oxaliplatin in combination with preoperative radiation therapy for rectal cancer
Track 12 Potential role of bevacizumab in the management of rectal cancer
Track 13 Local excision and radiation therapy for the management of rectal cancer
Track 14 Use of intraoperative radiation therapy for patients with locally advanced rectal cancer
Track 15 Importance of tailoring radiation fields to the individual patient’s anal and rectal anatomy
Track 16 Future directions in the management of colon and rectal cancers
     
J Randolph Hecht, MD
Clinical Professor of Medicine
Director, UCLA GI Oncology Program
Division of Hematology/Oncology
Department of Medicine
UCLA School of Medicine
Los Angeles, California
  
  Click here to download the entire interview  
Track 1 Introduction by Neil Love, MD
Track 2 Mechanism of action of small-molecule tyrosine kinase inhibitor PTK787/ZK
Track 3 Dynamic contrast-enhanced MRI as a surrogate marker for response to PTK787/ZK
Track 4 Mechanisms of VEGF inhibition
Track 5 Differences in the potential roles of VEGF receptors 1, 2 and 3
Track 6 Efficacy of single-agent PTK787/ZK
Track 7 Background and design of the CONFIRM-1 and CONFIRM-2 trials
Track 8 Early primary endpoint analysis of progression-free survival in CONFIRM-1
Track 9 Importance of pharmacokinetics in the development of VEGF inhibitors
Track 10 Correlation between progression-free survival and LDH levels in the CONFIRM trials
Track 11 Tolerability of PTK787/ZK
Track 12 Potential mechanisms of action of bevacizumab
Track 13 Potential rationale for rare bowel perforations associated with bevacizumab
Track 14 Incidence of arterial thrombotic events with bevacizumab
Track 15 Continuation of bevacizumab after disease progression
Track 16 Clinical use of bevacizumab in the adjuvant setting
Track 17 Duration of treatment with bevacizumab
Track 18 Clinical use of CAPOX in the adjuvant setting
Track 19 TREE-1 and TREE-2 trials evaluating oxaliplatin/fluoropyrimidine regimens as first-line therapy for advanced colorectal cancer
Track 20 Ongoing trials evaluating different combinations of biologic agents for advanced colorectal cancer
     
Josep Tabernero, MD
Clinical Investigator
Head of the Gastrointestinal Cancer Project
Medical Oncology Department
Vall d’Hebron University Hospital
Barcelona, Spain
  
  Click here to download the entire interview  
Track 1 Introduction by Neil Love, MD
Track 2 Background to the AVANT adjuvant trial: Safety and efficacy of CAPOX with bevacizumab
Track 3 Arteriovascular exclusionary criteria in the AVANT trial
Track 4 Adjuvant chemotherapy for patients with Stage II and III disease
Track 5 Clinical implications of the X-ACT adjuvant trial results
Track 6 Capecitabine dosing in the adjuvant setting
Track 7 Proposed trials of cetuximab in the adjuvant setting
Track 8 Incorporating bevacizumab/cetuximab therapies into clinical practice
Track 9 Clinical trial results of irinotecan-containing regimens in the adjuvant setting
Track 10 NSABP-C-07: Comparison of toxicity with FLOX versus FOLFOX
Track 11 Role of calcium and magnesium for oxaliplatin-related neurotoxicity in the adjuvant and metastatic settings
Track 12 Management of oxaliplatin-related neuropathy
Track 13 Safety and efficacy of neoadjuvant oxaliplatin for rectal cancer
Track 14 Future directions in the management of colorectal cancer